Serotonergic drugs and valvular heart disease - PubMed (original) (raw)
Review
Serotonergic drugs and valvular heart disease
Richard B Rothman et al. Expert Opin Drug Saf. 2009 May.
Abstract
Background: The serotonin (5-HT) releasers (+/-)-fenfluramine and (+)-fenfluramine were withdrawn from clinical use owing to increased risk of valvular heart disease. One prevailing hypothesis (i.e., the '5-HT hypothesis') suggests that fenfluramine-induced increases in plasma 5-HT underlie the disease.
Objective: Here, we critically evaluate the possible mechanisms responsible for fenfluramine-associated valve disease.
Methods: Findings from in vitro and in vivo experiments performed in our laboratory are reviewed. The data are integrated with existing literature to address the validity of the 5-HT hypothesis and suggest alternative explanations.
Conclusions: The overwhelming majority of evidence refutes the 5-HT hypothesis. A more likely cause of fenfluramine-induced valvulopathy is activation of 5-HT(2B) receptors on heart valves by the metabolite norfenfluramine. Future serotonergic medications should be designed to lack 5-HT(2B) agonist activity.
Figures
Figure 1
Dose-response effects of (+)-fenfluramine on extracellular levels of 5-HT, NE and DA in rat frontal cortex. Rats undergoing in vivo microdialysis sampling received i.v. injections of 1.0 and 3.0 mg/kg (+)-fenfluramine at time zero and 60 min, respectively. Dialysate samples were collected at 20 min intervals and immediately assayed for 5-HT, NE and DA. Data are peak effects measured 20 min after drug injection, expressed as mean ± SEM for N=6 rats. 5-HT levels are normalized to % of preinjection baseline. * = P<0.05 with respect to preinjection control. Figure modified from .
Figure 2
Dose-response effects of (+)-norfenfluramine on extracellular levels of 5-HT, NE and DA in rat frontal cortex. Rats undergoing in vivo microdialysis sampling received i.v. injections of 1.0 and 3.0 mg/kg (+)-norfenfluramine at time zero and 60 min. Dialysate samples were collected at 20 min intervals and immediately assayed for 5-HT, NE and DA. Data are peak effects measured 20 min after drug injection, expressed as mean ± SEM for N=6 rats. 5-HT levels are normalized to % of preinjection baseline. * = P<0.05 with respect to preinjection control. Figure modified from .
Figure 3
Effects of amphetamine analogs and fluoxetine on dialysate 5-HT levels measured in blood from conscious rats. Drug or saline vehicle was administered i.v. at time zero. Serial blood samples were withdrawn at 15 min intervals and dialyzed ex vivo. Dialysate samples were assayed for 5-HT. Data are peak effects measured in the first sample after drug injection, expressed as mean ± SEM for N=6 rats/group. 5-HT levels are normalized to % of preinjection baseline. * = P<0.05 compared to saline controls. Figure modified from .
Figure 4
Acute in vivo effects of (±)-fenfluramine on dialysate 5-HT levels measured in blood from conscious rats previously treated with chronic administration of (±)-fenfluramine (fen) or fluoxetine (fluox). For chronic treatments, drugs were dissolved in saline (fen) or 50% ethanol/saline (fluox), and administered s.c. via osmotic minipumps for 2 weeks. On day 14, fenfluramine was dissolved in saline and administered i.v. at 0 min. Serial blood samples were withdrawn at 15 min intervals and immediately dialyzed. Data are mean ± SEM for N=9 rats/group. For Baseline effects, 5-HT levels are normalized to % of vehicle control groups. For acute fenfluramine challenge effects, 5-HT data are peak effects measured 15 min postinjection expressed % of preinjection baseline. * = P<0.05 compared to saline-pretreated controls. Figure modified from .
Figure 5
Effects of chronic administration of (±)-fenfluramine (fen) and fluoxetine (fluox) on whole blood 5-HT levels measured 7 and 13 days after minipump implantation. Drugs were dissolved in saline (fen) or 50% ethanol/saline (fluox), and administered s.c. via osmotic minipumps for 2 weeks. Blood samples were withdrawn via indwelling jugular catheters and serum 5-HT was measured using double-antibody RIA methods. Data are mean ± SEM for N=9 rats/group expressed as % of vehicle control values. * = P<0.05 compared to saline or ethanol/saline controls at corresponding time points. Figure modified from .
Similar articles
- Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.
Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW. Fitzgerald LW, et al. Mol Pharmacol. 2000 Jan;57(1):75-81. Mol Pharmacol. 2000. PMID: 10617681 - Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. Rothman RB, et al. Circulation. 2000 Dec 5;102(23):2836-41. doi: 10.1161/01.cir.102.23.2836. Circulation. 2000. PMID: 11104741 - Serotonin releasing agents. Neurochemical, therapeutic and adverse effects.
Rothman RB, Baumann MH. Rothman RB, et al. Pharmacol Biochem Behav. 2002 Apr;71(4):825-36. doi: 10.1016/s0091-3057(01)00669-4. Pharmacol Biochem Behav. 2002. PMID: 11888573 Review. - 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.
Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL. Setola V, et al. Mol Pharmacol. 2003 Jun;63(6):1223-9. doi: 10.1124/mol.63.6.1223. Mol Pharmacol. 2003. PMID: 12761331 - Appetite suppressants, cardiac valve disease and combination pharmacotherapy.
Rothman RB, Baumann MH. Rothman RB, et al. Am J Ther. 2009 Jul-Aug;16(4):354-64. doi: 10.1097/MJT.0b013e31817fde95. Am J Ther. 2009. PMID: 19092640 Free PMC article. Review.
Cited by
- Benchmarking reverse docking through AlphaFold2 human proteome.
Luo Q, Wang S, Li HY, Zheng L, Mu Y, Guo J. Luo Q, et al. Protein Sci. 2024 Oct;33(10):e5167. doi: 10.1002/pro.5167. Protein Sci. 2024. PMID: 39276010 - Biological studies of clavine alkaloids targeting CNS receptors.
Tasker NR, Pazur EJ, Wipf P. Tasker NR, et al. Front Psychiatry. 2023 Nov 21;14:1286941. doi: 10.3389/fpsyt.2023.1286941. eCollection 2023. Front Psychiatry. 2023. PMID: 38076698 Free PMC article. - Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action.
Cameron LP, Benetatos J, Lewis V, Bonniwell EM, Jaster AM, Moliner R, Castrén E, McCorvy JD, Palner M, Aguilar-Valles A. Cameron LP, et al. J Neurosci. 2023 Nov 8;43(45):7472-7482. doi: 10.1523/JNEUROSCI.1384-23.2023. J Neurosci. 2023. PMID: 37940583 Free PMC article. Review. - μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges.
Salinsky LM, Merritt CR, Zamora JC, Giacomini JL, Anastasio NC, Cunningham KA. Salinsky LM, et al. Front Pharmacol. 2023 Oct 11;14:1239159. doi: 10.3389/fphar.2023.1239159. eCollection 2023. Front Pharmacol. 2023. PMID: 37886127 Free PMC article. Review. - A non-hallucinogenic LSD analog with therapeutic potential for mood disorders.
Lewis V, Bonniwell EM, Lanham JK, Ghaffari A, Sheshbaradaran H, Cao AB, Calkins MM, Bautista-Carro MA, Arsenault E, Telfer A, Taghavi-Abkuh FF, Malcolm NJ, El Sayegh F, Abizaid A, Schmid Y, Morton K, Halberstadt AL, Aguilar-Valles A, McCorvy JD. Lewis V, et al. Cell Rep. 2023 Mar 28;42(3):112203. doi: 10.1016/j.celrep.2023.112203. Epub 2023 Mar 6. Cell Rep. 2023. PMID: 36884348 Free PMC article.
References
- Weiger WA. Serotonergic modulation of behaviour: a phylogenetic overview. Biol Rev Camb Philos Soc. 1997 Feb;72(1):61–95. - PubMed
- Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002 Apr;71(4):533–54. - PubMed
- Nichols DE, Nichols CD. Serotonin receptors. Chem Rev. 2008 May;108(5):1614–41. - PubMed
- Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. NEnglJMed. 1997;337(9):581–8. - PubMed
- Connolly HM, McGoon MD. Obesity drugs and the heart. Curr Probl Cardiol. 1999;24:745–92. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical